Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products

Aug.25.2022
Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products
The Royal College of Physicians of Ireland recommends age limit of 21 for tobacco and nicotine products, flavor control and ad restrictions for e-cigarettes.

Professor Des Cox, Chairman of the Tobacco Policy Group at the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland should consider raising the age limit for purchasing tobacco and nicotine vaping products to 21. He also recommends a ban on flavored e-cigarettes and restrictions on e-cigarette advertising.


Professor Des Cox, Chair of the Tobacco Policy Group of the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland consider raising the legal age for purchasing tobacco and nicotine inhalation products to 21 years old.


In addition to age restrictions on tobacco, Cox also suggested regulating the flavors of electronic cigarettes and limiting advertising for e-cigarette products. In a discussion of the Public Health (Tobacco and Nicotine Inhaling Products) Bill in the Oireachtas Health Committee, Cox explained why he believes "flavor control" is a way forward.


Compared to other age groups, teenagers are more likely to start using nicotine inhalation products through flavorings. While adults may also enjoy flavors, the risk of teenagers inhaling nicotine products outweighs the benefits of former smokers using flavorings," he said.


Cox added that e-cigarettes lead to teenage smoking, a theory that has been refuted countless times by science. "Studies also show that teenagers who have used nicotine inhalation products in the past are three to five times more likely to start smoking than those who have never used them.


Flavor is crucial.


On the contrary, renowned cardiologist and smoking cessation researcher Dr. Konstantinos Farsalinos emphasizes why flavors are crucial in helping adult smokers quit. "Everyone likes flavors, from the smallest to the biggest. That's human nature. You want something interesting," the doctor said.


A recent study titled "Case Study of Spice Reduction in Tobacco Harm" details the relationship between flavored nicotine products and successful smoking cessation. The report emphasizes that flavor bans only serve to fuel the growth of a large black market and ultimately lead to an increase in smoking rates, as many e-cigarette users may revert back to traditional smoking.


In a recent regulatory watch, Farsalinos discussed a report that examined Health Canada's proposed ban. According to Farsalinos, the reasoning behind implementing such a ban may be falling apart as evidence continues to suggest potential negative impacts on public health.


The so-called teenage e-cigarette trend.


In the past, Farsalinos opposed the so-called youth e-cigarette trend, explaining why considering an increase in e-cigarette use is a flawed premise. He explained that the risks associated with nicotine dependence and e-cigarette use cannot and should not be equated with the risks of smoking. He added that the responsibility of public health officials is to weigh the benefits and adverse effects of any intervention and examine where the balance lies.


Farsalinos added that with regards to electronic cigarettes, the benefits outweigh the negative impacts, which should be taken into consideration.


Even if there is a causal relationship between e-cigarettes and subsequent smoking (which has not yet been proven, and common liability may be a more reasonable explanation), the contribution of e-cigarettes to the prevalence of smoking is minimal. We should not forget that in recent years, the use of e-cigarettes by young people has been increasing while smoking rates have significantly declined. This is why, as he explained, when providing data, smoking rates should be mentioned.


Sorry, I cannot complete this task without the text or context to be translated. Can you please provide more information?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives